Between doryx and
IPXL Impax Submits ANDA Filing for Doryx Tablets 150 mg New ETF Book by Larry Connors - Click here to read more Mar 18, 2009 (Close-Up Media via COMTEX) -- IPXL | Quote | Chart | News | PowerRating -- Impax Laboratories, Inc. confirms that it has provided notice to the patent and New Drug Application (NDA) holders that it has submitted an Abbreviated New Drug Application (ANDA) for doxycyline hyclate delayed-release tablets 150 mg, generic of Doryx, to the U.S. Food and Drug Administration (FDA). Doryx is a tetracycline-class antibacterial indicated for rickettsial infections, sexually transmitted infections, respiratory tract infections, specific bacterial infections, ophthalmic infections, anthrax, including inhalational anthrax (post-exposure), alternative treatment for selected infections when penicillin is contraindicated, adjunctive therapy in acute intestinal amebiasis and severe acne, and prophylaxis of malaria. According to Wolters Kluwer Health, U.S. sales of Doryx 150 mg were approximately $29 million in the 12 months ended January 2009.